Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.

The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns. Participants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.

Inclusion Criteria: * Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status. Exclusion Criteria: * Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure). * Concomitant medications that would interfere with cognitive assessments. * A prior diagnosis of AD and related disorders or other neurodegenerative disease.